Day: August 25, 2020

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.33821-94-2,2-(3-Bromopropoxy)tetrahydro-2H-pyran,as a common compound, the synthetic route is as follows.

A mixture of D147 (1 .00 g, 5.02 mmol), 2-(3-bromopropoxy)tetrahydro-2H-pyran (1 .12 g, 5.02 mmol) and K2CO3(1 .39 g, 10.04 mmol) in DMF (20 mL) was heated at 80 C for 3 hrs. The reaction mixture was poured into ice water (60 mL), and extracted with EtOAc (2×30 mL). The organic layer was washed with brine (3×40 mL), dried, filtered and concentrated. The crude was purified by column chromatography on silica gel (PE: EtOAc= 1 : 1 ) to give the title compound as a yellow solid (1 .526 g, yield 89%).

33821-94-2 2-(3-Bromopropoxy)tetrahydro-2H-pyran 2777988, aTetrahydropyrans compound, is more and more widely used in various.

Reference£º
Patent; GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED; DING, Xiao; HO, Ming-Hsun; REN, Feng; YU, Haihua; ZHAN, Yang; (290 pag.)WO2019/12093; (2019); A1;,
Tetrahydropyran – Wikipedia
Tetrahydropyran – an overview | ScienceDirect Topics

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.110238-91-0,Methyl tetrahydro-2H-pyran-4-carboxylate,as a common compound, the synthetic route is as follows.

Step 1: Synthesis of (Tetrahydro-pyran-4-yl)-methanol To a solution of 250 mL of LiAlH4 (2.3M solution in THF, 0.575 mol) in THF (200 mL) is added dropwise a solution of 130 mL (0.974 mol) of tetrahydro-pyran-4-carboxylic acid methyl ester in THF (900 mL) under nitrogen atmosphere (CAUTION: highly exothermic[reaction]). The temperature is kept at 40-45 C. with an ice-bath. Upon complete addition, the reaction is stirred at room temperature for 1.5 h. The reaction is cooled in an ice-bath and quenched with addition of water (22 mL), 15% aqueous NaOH solution (21 mL) and water (66 mL). The resulting precipitate is removed by filtration through Celite and is rinsed with THF (300 mL). The filtrate is concentrated under reduced pressure to afford 102.5 g of (tetrahydro-pyran-4-yl)-methanol as a clear oil. Yield: 91%; 1H-NMR (400 MHz, CHLOROFORM-d) delta ppm 1.20-1.39 (2H, m), 1.56-1.83 (3H, m), 2.03 (1H, br. s.), 3.29-3.52 (4H, m), 3.89-4.05 (2H, m),

110238-91-0 Methyl tetrahydro-2H-pyran-4-carboxylate 2773520, aTetrahydropyrans compound, is more and more widely used in various.

Reference£º
Patent; Boehringer Ingelheim International GmbH; US2010/76029; (2010); A1;,
Tetrahydropyran – Wikipedia
Tetrahydropyran – an overview | ScienceDirect Topics

29943-42-8, Dihydro-2H-pyran-4(3H)-one is a Tetrahydropyrans compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

Step A: Preparation of 4-methylenetetrahydro-2H-pyran: A solution of dihydro-2H-pyran-4(3H)-one (2.50g; 25.0mmol) in THF (50mL) was sparged with nitrogen for 15 minutes. The solution was cooled to 5 C under nitrogen with stirring. A solution of Tebbe reagent (bis(cyclopentadienyl)-mu-chloro(dimethylaluminum)-mu-methylenetitanium) (25.0 mmol; 0.50 M solution in toluene; Sigma- Aldrich Chemical Co.) was added. The mixture was allowed to warm to ambient temperature. Ether was added (400 mL). The reagent was quenched by the careful addition of 0.1M sodium hydroxide (10 mL). (The quench is highly exothermic with considerable effervescence). The resulting solution was dried (sodium sulfate) and filtered through a mixture of Celite and alumina washing the filter cake with ether. The filtrate was partially concentrated to remove the majority of the ether at 50 C and a pressure of 580 mm Hg. The resulting mixture was diluted with pentane, filtered through Celite and then partially concentrated as previously (taking care not to lose the volatile product). The resulting solution in toluene/pentane was continued to the next step without characterization of the product.

29943-42-8 Dihydro-2H-pyran-4(3H)-one 121599, aTetrahydropyrans compound, is more and more widely used in various.

Reference£º
Patent; ARRAY BIOPHARMA INC.; BOYS, Mark Laurence; BURGESS, Laurence, E.; GRONEBERG, Robert, D.; HARVEY, Darren, M.; HUANG, Lily; KERCHER, Timothy; KRASER, Christopher, F.; LAIRD, Ellen; TARLTON, Eugene; ZHAO, Qian; WO2011/130146; (2011); A1;,
Tetrahydropyran – Wikipedia
Tetrahydropyran – an overview | ScienceDirect Topics

19752-84-2, Tetrahydro-2H-pyran-3-ol is a Tetrahydropyrans compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

To a solution of tetrahydro-2H-pyran-3-ol (2.0 g) in DCM (100 mL) was added TEA(4.0 g) and methanesulfonyl chloride (2.7 g) at 0C under a nitrogen atmosphere. The resultingmixture was stirred at this temperature for 30 mins, and then quenched with aq. NaHCO3 solution. The mixture was extracted with DCM (2×50 mL). The combined organic phases were washed, dried and concentrated to afford tetrahydro-2H-pyran-3-yl methanesulfonate (3.2 g) as a brown oil.

The synthetic route of 19752-84-2 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED; CHEN, Weichun; IGBOKO, Ebere F; LIN, Xichen; LU, Hongfu; REN, Feng; WREN, Paul Bryan; XU, Zhongmiao; YANG, Ting; ZHU, Lingdong; WO2015/181186; (2015); A1;,
Tetrahydropyran – Wikipedia
Tetrahydropyran – an overview | ScienceDirect Topics

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.33024-60-1,Tetrahydro-2H-pyran-4-amine hydrochloride,as a common compound, the synthetic route is as follows.

Intermediate [II] (43mg, 0. [114MMOL)] was reacted with 4-amino-tetrahydropyran hydrochloride salt (31 mg, 0. [23MMOL)] according to general procedure C (0. [45MMOL] DIPEA in isopropanol, heated for 2.5hours). Purification by preparative HPLC gave the desired product (purine N-9 linked to the 1-position of ribose) as a yellow gum, [(18MG,] 0.041 mmol, 36percent). m/z 444 [(MH +),] LCMS retention time 2.64min. The isomeric product (purine [N-7-LINKED)] was also obtained as a gum, (6mg, 0. [014MMOL,] 12percent). m/z 444 (MH +), LCMS retention time 2.52min.

The synthetic route of 33024-60-1 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; GLAXO GROUP LIMITED; WO2004/26890; (2004); A1;,
Tetrahydropyran – Wikipedia
Tetrahydropyran – an overview | ScienceDirect Topics

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.185815-59-2,4-Isobutyldihydro-2H-pyran-2,6(3H)-dione,as a common compound, the synthetic route is as follows.

Example 3: Preparation of (3RV5-methyl-3-r2-oxo-2{r(lR)-l-phenylethyl1ammo|ethvD hexanoic acid compound (24); [0077] A three-necked flask equipped with an addition funnel, thermometer pocket, drying tube and a mechanical stirrer, was charged with toluene (100 ml), (R)-(H-)- phenylethylamine (35.58 g, 0.294 mole) and 4-dimethylaminopyridme (0.18 g, 0.00147 mole). The mixture was cooled to a temperature of 0-50C, followed by addition of a solution of 3-isobutyl glutaric anhydride (25 g, 0.147 mole) in toluene (25 ml), over a period of 15-20 minutes, and stirring for additional 1.5-2 hours, at a temperature of 0-5C. The mixture was then extracted with 2.5-3.0 percent aqueous solution OfNaHCO3 solution (500 ml), and the aqueous phase was washed with toluene (1 x 100 ml). The pH of the aqueous phase was adjusted to 2-2.5 by adding a 1-12N solution of hydrochloric acid. The aqueous phase was further extracted with ethyl acetate (1 x 150 ml and 1 x 50 ml), followed by drying the combined ethyl acetates extracts over anhydrous sodium sulfate, and stripping off the solvents, to obtain a residue. The residue was crystallized from ethyl acetate and toluene mixture to get 28.4g (66.4 percent yield) of a white solid of (3R)-5-methyl-3-(2-oxo-2- {[(lR)-l-phenylethyl]amino}ethyl)hexanoic acid with an optical purity of 99.6 percent, as measured by chiral HPLC.

The synthetic route of 185815-59-2 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; TEVA PHARMACEUTICAL INDUSTRIES LTD.; TEVA PHARMACEUTICALS USA, INC.; WO2007/35789; (2007); A1;,
Tetrahydropyran – Wikipedia
Tetrahydropyran – an overview | ScienceDirect Topics

65412-03-5, 4-(2-Aminoethyl)tetrahydro-2H-pyran is a Tetrahydropyrans compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

Example 63-(Phenylsulfonyl)-lambda/-[2-(tetrahydro-2H-pyran-4-yl)ethyl]-8-quinolinamine hydrochloride (E6)To 8-fluoro-3-(phenylsulfonyl)quinoline (D2) (300 mg), potassium carbonate (0.288 g: 2 eq) and 4-amino-ethyl[2-(tetrahydro-2H-pyran-4-yl)ethyl]amine (Apollo Scientific) (0.269 g, 2 eq) in DMSO(3 ml) were added to a 5 ml microwave vial. The mixture was heated at 18O0C under microwave irradiation for 1 hour. The reaction mixture was diluted with sodium hydrogen carbonate (20 ml) and extracted with ethyl acetate (3 x 20 ml). The ethyl acetate layers were combined and evaporated. The residue obtained was purified using the Flashmaster Il (gradient 10-80% ethyl acetate on 50 g silica column) to give the free base of the title compound (0.255 g).NMR (400MHz1 Chloroform-d6) delta 1.31-1.41 (2H1 m), 1.65-1.71 (5H, m), 3.33-3.49 (4H, m), 3.94-3.97 (2H, m), 6.93 (1 H, d), 7.22 (1 H1 d), 7.52-7.62 (4H1 m), 8.00-8.03(2H, m), 8.75 (1 H, d), 9.07 (1 H, d) EPO LC/MS, t = 3.58min, Molecular ion observed (MH+) = 497 consistent with the molecular formula C22H24N2O3S

As the paragraph descriping shows that 65412-03-5 is playing an increasingly important role.

Reference£º
Patent; GLAXO GROUP LIMITED; WO2007/39220; (2007); A1;,
Tetrahydropyran – Wikipedia
Tetrahydropyran – an overview | ScienceDirect Topics

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.2081-44-9,Tetrahydro-2H-pyran-4-ol,as a common compound, the synthetic route is as follows.

To a solution of tetrahydro-4H-pyran-4-ol (3.62 g) and triethylamine (5.6 mL) in tetrahydrofuran (35 mL) was added methanesulfonyl chloride (2.93 mL) under ice-cooling, and the mixture was stirred at room temperature for 1 hour. The insoluble material was removed by filtration. To the filtrate were addedN,N-dimethylformamide (70 mL), 4-benzyloxy-2-hydroxybenzaldehyde (5.39 g) and cesium carbonate (23 g), and the mixture was stirred at 80C for 12 hours. The reaction mixture was poured into water, and the resulting mixture was extracted with diethyl ether. The extract was washed with water and brine, and dried over anhydrous magnesium sulfate. The solvent was removed under reduced pressure, and the residue was purified by column chromatography on silica gel (eluent: n-hexane/ethyl acetate = 4/1 – 2/1) to give 4-benzyloxy-2-(tetrahydro-4H-pyran-4-yl-oxy)benzaldehyde (4.58 g). This material was dissolved in ethanol (70 mL). To the solution was added sodium borohydride (0.28 g) under ice-cooling, and the mixture was stirred at room temperature for 3 hours. To the reaction mixture was added methanol, and the resulting mixture was concentrated under reduced pressure. A saturated aqueous sodium hydrogen carbonate solution was added to the residue, and the mixture was extracted with diethyl ether. The extract was washed with a saturated aqueous sodium hydrogen carbonate solution, water and brine successively, and dried over anhydrous magnesium sulfate. The solvent was removed under reduced pressure, and the residue was purified by column chromatography on silica gel (eluent: n-hexane/ethyl acetate = 3/1 – 1/1) to give the title compound (4.45 g).1H-NMR (CDCl3) delta ppm: 1.75-1.85 (2H, m), 1.95-2.05 (2H, m), 2.11 (1H, t, J=6.3Hz), 3.5-3.65 (2H, m), 3.9-4.0 (2H, m), 4.45-4.55 (1H, m), 4.63 (2H, d, J=6.3Hz), 5.05 (2H, s), 6.5-6.6 (2H, m), 7.19 (1H, d, J=7.7Hz), 7.3-7.45 (5H, m)

2081-44-9 Tetrahydro-2H-pyran-4-ol 74956, aTetrahydropyrans compound, is more and more widely used in various.

Reference£º
Patent; Kissei Pharmaceutical Co., Ltd.; EP1544208; (2005); A1;,
Tetrahydropyran – Wikipedia
Tetrahydropyran – an overview | ScienceDirect Topics

65412-03-5, 4-(2-Aminoethyl)tetrahydro-2H-pyran is a Tetrahydropyrans compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

Step 3. Preparation of 6-(quinolin-4-yloxy)-N-(2-(tetrahydro-2H-pyran-4-yl)ethyl)benzo[d]thiazol-2-amine To the reaction mixture of 2-(methylsulfinyl)-6-(quinolin-4-yloxy)benzo[d]thiazole (11.5 mg, 0.034 mmol) in 0.4 mL of NMP was added (DIPEA) diisopropylethylamine (15 uL, 0.084 mmol) and 2-(tetrahydro-2H-pyran-4-yl)ethanamine (17.4 mg, 0.134 mmol). The reaction mixture was stirred at 100 C. for 20 hours or until done by LC. The crude reaction mixture was filtered, purified on prep HPLC and lyophilized to give 6-(quinolin-4-yloxy)-N-(2-(tetrahydro-2H-pyran-4-yl)ethyl)benzo[d]thiazol-2-amine as TFA salt (5.1 mg). ES/MS m/z 406.1 (MH+).

65412-03-5 4-(2-Aminoethyl)tetrahydro-2H-pyran 2773198, aTetrahydropyrans compound, is more and more widely used in various.

Reference£º
Patent; Novartis AG; US2008/45528; (2008); A1;,
Tetrahydropyran – Wikipedia
Tetrahydropyran – an overview | ScienceDirect Topics

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.125995-03-1,Atorvastatin lactone,as a common compound, the synthetic route is as follows.

Atorvastatin lactone (2.0 g) was dissolved in toluene (12.0 ml). To the clear solution so obtained, dimethyl sulfoxide (0.34 ml) was added under stirring. After the addition was complete the precipitated material was further stirred. The product was filtered under suction and dried under vacuum in oven. Crystalline atorvastatin lactone (1.8 g) as Form I was obtained. M.pt. 127-13O0C.

The synthetic route of 125995-03-1 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; JUBILANT ORGANOSYS LIMITED; WO2006/67795; (2006); A2;,
Tetrahydropyran – Wikipedia
Tetrahydropyran – an overview | ScienceDirect Topics